A Multicenter Study of Glucocerebrosidase Mutations i

JAMA Neurology

70, 727

DOI: 10.1001/jamaneurol.2013.1925

Citation Report

#	Article	IF	Citations
1	Parkinson's disease dementia: convergence of Î±-synuclein, tau and amyloid-Î² pathologies. Nature Reviews Neuroscience, 2013, 14, 626-636.	4.9	673
2	Update on Dementia with Lewy Bodies. Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2, 196-204.	0.7	17
4	Early-onset dementias: diagnostic and etiological considerations. Alzheimer's Research and Therapy, 2013, 5, S7.	3.0	47
5	Predicting parkinsonism: New opportunities from Gaucher disease. Molecular Genetics and Metabolism, 2013, 109, 235-236.	0.5	5
6	Hypercoagulability, Parkinsonism, and Gaucher Disease. Seminars in Thrombosis and Hemostasis, 2013, 39, 928-934.	1.5	10
7	The pallidopyramidal syndromes. Current Opinion in Neurology, 2013, 26, 381-394.	1.8	25
8	From the Genetic Code to Neuromics. JAMA Neurology, 2013, 70, 684.	4.5	0
9	Glucocerebrosidase Mutations. JAMA Neurology, 2013, 70, 686.	4.5	3
10	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	1.4	178
11	Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain, 2014, 137, 1481-1495.	3.7	258
12	Cognition in movement disorders: Where can we hope to be in ten years?. Movement Disorders, 2014, 29, 704-711.	2.2	15
13	Dementia with Lewy Bodies. Seminars in Neurology, 2014, 34, 182-188.	0.5	44
14	Sphingolipids and lysosomal pathologies. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 799-810.	1.2	88
15	Dementia in Parkinsonâ€™s Disease and Atypical Parkinsonism. , 2014, , 179-197.		1
16	Advances in the Genetics of Parkinson's Disease: A Guide for the Clinician. Movement Disorders Clinical Practice, 2014, 1, 3-13.	0.8	17
17	Glucocerebrosidase is shaking up the synucleinopathies. Brain, 2014, 137, 1304-1322.	3.7	128
18	Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease. Neurobiology of Aging, 2014, 35, 935.e3-935.e8.	1.5	69
19	Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations. Human Molecular Genetics, 2014, 23, R47-R53.	1.4	57

#	Article	IF	Citations
20	Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. Experimental Neurology, 2014, 262, 75-83.	2.0	72
21	Reduced glucocerebrosidase is associated with increased Î±-synuclein in sporadic Parkinsonâ€™s disease. Brain, 2014, 137, 834-848.	3.7	397
22	Disease variants in genomes of 44 centenarians. Molecular Genetics & Genomic Medicine, 2014, 2, 438-450.	0.6	58
23	Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism and Related Disorders, 2014, 20, 1215-1220.	1.1	63
24	Mutations in Niemann Pick type C gene are risk factor for Alzheimerâ€™s disease. Medical Hypotheses, 2014, 83, 559-562.	0.8	17
25	Urinary thyroid hormone parameters test for evaluating the thyroid function during pregnancy. Systems Biology in Reproductive Medicine, 2014, 60, 171-176.	1.0	2
26	Glucocerebrosidase depletion enhances cell-to-cell transmission of Î±-synuclein. Nature Communications, 2014, 5, 4755.	5.8	157
27	Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease. JIMD Reports, 2014, 16, 31-38.	0.7	12
28	The significance of GBA for Parkinson's disease. Journal of Inherited Metabolic Disease, 2014, 37, 643-648.	1.7	36
30	Studies of glucocerebrosidase provide new therapeutic targets for parkinsonism. Future Neurology, 2014, 9, 407-409.	0.9	0
31	Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Human Molecular Genetics, 2014, 23, 3943-3957.	1.4	79
32	iPSC-derived neurons from GBA1-associated Parkinsonâ€™s disease patients show autophagic defects and impaired calcium homeostasis. Nature Communications, 2014, 5, 4028.	5.8	436
33	Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant Î²-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease. Scientific Reports, 2015, 5, 10903.	1.6	107
34	Genetic Markers in Biological Fluids for Aging-Related Major Neurocognitive Disorder. Current Alzheimer Research, 2015, 12, 200-209.	0.7	8
35	Beta-Glucocerebrosidase Gene Mutations P.Asn409Ser and P.Leu483Pro in Polish Patients with Parkinson's Disease. Journal of Neurology and Neuroscience, 2015, 06, .	0.4	0
36	Genetics Underlying Atypical Parkinsonism and Related Neurodegenerative Disorders. International Journal of Molecular Sciences, 2015, 16, 24629-24655.	1.8	21
37	Lysosomal Enzyme Glucocerebrosidase Protects against AÎ²1-42 Oligomer-Induced Neurotoxicity. PLoS ONE, 2015, 10, e0143854.	1.1	12
38	Brain-derived neurotrophic factor expression increases after enzyme replacement therapy in Gaucher disease. Journal of Neuroimmunology, 2015, 278, 190-193.	1.1	11

#	Article	IF	Citations
39	Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle. Progress in Neurobiology, 2015, 125, 47-62.	2.8	63
40	Structural Features of Membrane-bound Glucocerebrosidase and Î±-Synuclein Probed by Neutron Reflectometry and Fluorescence Spectroscopy. Journal of Biological Chemistry, 2015, 290, 744-754.	1.6	44
41	Fluorescence-Quenched Substrates for Live Cell Imaging of Human Glucocerebrosidase Activity. Journal of the American Chemical Society, 2015, 137, 1181-1189.	6.6	59
42	Evolution of Prodromal Clinical Markers of Parkinson Disease in aGBAMutationâ€“Positive Cohort. JAMA Neurology, 2015, 72, 201.	4.5	180
43	The endosomal pathway in Parkinson's disease. Molecular and Cellular Neurosciences, 2015, 66, 21-28.	1.0	71
44	Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends in Genetics, 2015, 31, 140-149.	2.9	193
45	Genetics of Parkinsonâ€™s Disease. , 2015, , 19-34.		3
46	Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells. Neurobiology of Disease, 2015, 82, 235-242.	2.1	76
47	Genetics of Parkinson Disease andÂRelatedÂDiseases. , 2015, , 769-778.		1
48	Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease. Human Molecular Genetics, 2015, 24, R32-R44.	1.4	73
49	Variants associated with Gaucher disease in multiple system atrophy. Annals of Clinical and Translational Neurology, 2015, 2, 417-426.	1.7	90
50	Glucocerebrosidase and Parkinson disease: Recent advances. Molecular and Cellular Neurosciences, 2015, 66, 37-42.	1.0	184
51	Understanding and managing parkinsonism in patients with glucocerebrosidase mutations. Expert Opinion on Orphan Drugs, 2015, 3, 549-562.	0.5	1
52	Selective loss of glucocerebrosidase activity in sporadic Parkinsonâ€™s disease and dementia with Lewy bodies. Molecular Neurodegeneration, 2015, 10, 15.	4.4	120
54	Interaction Between Mitochondria and Autophagy. Current Topics in Neurotoxicity, 2015, , 41-61.	0.4	0
55	Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant Î±-synuclein and aggravates neurodegeneration in aDrosophilamodel of Parkinson's disease. Human Molecular Genetics, 2015, 24, 6675-6686.	1.4	81
56	Lewy body dementias. Lancet, The, 2015, 386, 1683-1697.	6.3	422
57	Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission of Î±-synuclein aggregates. Cell Death and Disease, 2015, 6, e1901-e1901.	2.7	58

#	Article	IF	Citations
58	Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. Parkinsonism and Related Disorders, 2015, 21, 1427-1434.	1.1	20
59	Sleep, Cognition and Dementia. Current Psychiatry Reports, 2015, 17, 97.	2.1	81
60	A novel common variant in DCST2 is associated with length in early life and height in adulthood. Human Molecular Genetics, 2015, 24, 1155-1168.	1.4	109
61	Genetic Convergence of Parkinsonâ€™s Disease and Lysosomal Storage Disorders. Molecular Neurobiology, 2015, 51, 1554-1568.	1.9	22
62	Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment. Movement Disorders, 2016, 31, 830-835.	2.2	32
63	A new glucocerebrosidase deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease. DMM Disease Models and Mechanisms, 2016, 9, 769-78.	1.2	20
64	Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinsonâ€™s disease. Human Molecular Genetics, 2016, 25, ddw124.	1.4	44
65	Clinical studies of GBA1-associated parkinsonism: progress and challenges. Neurodegenerative Disease Management, 2016, 6, 1-4.	1.2	4
66	Clinical course and prognosis in patients with Gaucher disease and parkinsonism. Neurology: Genetics, 2016, 2, e57.	0.9	29
67	Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Expert Review of Proteomics, 2016, 13, 471-479.	1.3	51
68	Neuropsychiatric characteristics of GBA-associated Parkinson disease. Journal of the Neurological Sciences, 2016, 370, 63-69.	0.3	50
69	Identification of Modifier Genes in a Mouse Model of Gaucher Disease. Cell Reports, 2016, 16, 2546-2553.	2.9	52
70	High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews. JAMA Neurology, 2016, 73, 1448.	4.5	48
71	The Clinical Profile of GBA-Related Lewy Body Disorders. JAMA Neurology, 2016, 73, 1403.	4.5	1
72	The lysosomal storage disease continuum with ageing-related neurodegenerative disease. Ageing Research Reviews, 2016, 32, 104-121.	5.0	34
73	New Directions in Gaucher Disease. Human Mutation, 2016, 37, 1121-1136.	1.1	25
74	Parkinson's disease: acidâ€glucocerebrosidase activity and alphaâ€synuclein clearance. Journal of Neurochemistry, 2016, 139, 198-215.	2.1	59
75	Genetics in Parkinson disease: Mendelian versus nonâ€Mendelian inheritance. Journal of Neurochemistry, 2016, 139, 59-74.	2.1	390

#	Article	IF	Citations
76	Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease. Movement Disorders, 2016, 31, 1610-1618.	2.2	47
77	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
78	Catastrophic cliffs: a partial suggestion for selective vulnerability in neurodegenerative diseases. Biochemical Society Transactions, 2016, 44, 659-661.	1.6	12
79	A New Glucocerebrosidase Chaperone Reduces Â-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. Journal of Neuroscience, 2016, 36, 7441-7452.	1.7	189
80	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinsonâ€™s disease and increase susceptibility to dementia in a Flanders-Belgian cohort. Neuroscience Letters, 2016, 629, 160-164.	1.0	34
81	Mitochondrial Dysfunction in Neurodegenerative Disorders. , 2016, , .		3
82	Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies. Neurobiology of Disease, 2016, 94, 55-62.	2.1	55
83	The Deleterious Duo of Neurodegeneration: Lysosomes and Mitochondria. , 2016, , 279-300.		2
84	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.4	32
85	GBA Mutations Are Associated With Earlier Onset and Male Sex in Dementia With Lewy Bodies. Movement Disorders, 2016, 31, 1066-1070.	2.2	34
86	<scp>GBA</scp>â€associated parkinsonism and dementia: beyond Î±â€synucleinopathies?. European Journal of Neurology, 2016, 23, 520-526.	1.7	9
87	Characterization of the complex formed by Î²-glucocerebrosidase and the lysosomal integral membrane protein type-2. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3791-3796.	3.3	45
88	Glucocerebrosidase enzyme activity in GBA mutation Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2016, 28, 185-186.	0.8	33
89	Mutations of glucocerebrosidase gene and susceptibility to Parkinsonâ€™s disease: An updated meta-analysis in a European population. Neuroscience, 2016, 320, 239-246.	1.1	33
90	ER Stress and Autophagic Perturbations Lead to Elevated Extracellular Î±-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons. Stem Cell Reports, 2016, 6, 342-356.	2.3	279
91	Advances in GBA-associated Parkinson's disease â€“ Pathology, presentation and therapies. Neurochemistry International, 2016, 93, 6-25.	1.9	46
92	Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiology of Disease, 2016, 90, 43-50.	2.1	79
93	The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease. Neuron, 2017, 93, 737-746.	3.8	127

#	Article	IF	Citations
94	Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2699-2704.	3.3	165
95	Lewy Body Dementias. Focus (American Psychiatric Publishing), 2017, 15, 85-100.	0.4	2
96	Lewy body dementia. , 2017, , 175-198.		2
97	Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Human Molecular Genetics, 2017, 26, 2603-2615.	1.4	37
98	Induced pluripotent stem cell-based modeling of neurodegenerative diseases: a focus on autophagy. Journal of Molecular Medicine, 2017, 95, 705-718.	1.7	18
99	Induced pluripotent stem cell models of lysosomal storage disorders. DMM Disease Models and Mechanisms, 2017, 10, 691-704.	1.2	23
100	Frequency of GBA Variants in Autopsyâ€proven Multiple System Atrophy. Movement Disorders Clinical Practice, 2017, 4, 574-581.	0.8	47
101	Ten plus one challenges in diseases of the lysosomal system. Molecular Genetics and Metabolism, 2017, 120, 38-46.	0.5	4
102	The Transcellular Propagation and Intracellular Trafficking of Î±-Synuclein. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024380.	2.9	28
103	Endoâ€lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?. Journal of Neurochemistry, 2017, 140, 703-717.	2.1	112
104	A â€œdoseâ€•effect of mutations in the GBA gene on Parkinson's disease phenotype. Parkinsonism and Related Disorders, 2017, 36, 47-51.	1.1	78
105	Parkinson's disease susceptibility variants and severity of Lewy body pathology. Parkinsonism and Related Disorders, 2017, 44, 79-84.	1.1	17
106	Lysosomal defects in ATP13A2 and GBA associated familial Parkinsonâ€™s disease. Journal of Neural Transmission, 2017, 124, 1395-1400.	1.4	14
107	An update on the genetics of dementia with Lewy bodies. Parkinsonism and Related Disorders, 2017, 43, 1-8.	1.1	31
108	Overview of Inflammation in Neurometabolic Diseases. Seminars in Pediatric Neurology, 2017, 24, 207-213.	1.0	16
109	The Lewy body dementias. , 0, , 278-300.		0
110	A clinicopathological approach to the diagnosis of dementia. Nature Reviews Neurology, 2017, 13, 457-476.	4.9	233
111	Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers. Neurobiology of Aging, 2017, 58, 239.e1-239.e7.	1.5	6

#	Article	IF	Citations
112	Gaucher disease: Progress and ongoing challenges. Molecular Genetics and Metabolism, 2017, 120, 8-21.	0.5	112
113	Glucocerebrosidase Mutations in Parkinson Disease. Journal of Parkinson's Disease, 2017, 7, 411-422.	1.5	108
114	The Spectrum of Neurological Manifestations Associated with Gaucher Disease. Diseases (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	1.0	54
115	Lipid Involvement in Neurodegenerative Diseases of the Motor System: Insights from Lysosomal Storage Diseases. Frontiers in Molecular Neuroscience, 2017, 10, 356.	1.4	32
116	Glucocerebrosidase Gene Mutations and Parkinsonismâ˜†. , 2017, , .		0
117	Current concepts and controversies in the pathogenesis of Parkinsonâ€™s disease dementia and Dementia with Lewy Bodies. F1000Research, 2017, 6, 1604.	0.8	35
118	Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinsonâ€™s Disease Models. Cell Reports, 2018, 22, 2066-2079.	2.9	167
119	Recent advances in the diagnosis and management of Gaucher disease. Expert Review of Endocrinology and Metabolism, 2018, 13, 107-118.	1.2	78
120	Glucocerebrosidase gene variants are accumulated in idiopathic REM sleep behavior disorder. Parkinsonism and Related Disorders, 2018, 50, 94-98.	1.1	23
121	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. Movement Disorders, 2018, 33, 660-677.	2.2	275
122	Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications. Neuroscientist, 2018, 24, 540-559.	2.6	81
123	The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS Journal, 2018, 285, 3591-3603.	2.2	99
124	Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Scientific Reports, 2018, 8, 1385.	1.6	74
125	Pathological role of lipid interaction with Î±-synuclein in Parkinson's disease. Neurochemistry International, 2018, 119, 97-106.	1.9	53
126	GBA1 deficiency negatively affects physiological Î±-synuclein tetramers and related multimers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 798-803.	3.3	139
127	Changes of the peripheral blood mononuclear cells membrane fluidity from type 1 Gaucher disease patients: an electron paramagnetic resonance study. Biological Chemistry, 2018, 399, 447-452.	1.2	5
128	D409H GBA1 mutation accelerates the progression of pathology in A53T Î±-synuclein transgenic mouse model. Acta Neuropathologica Communications, 2018, 6, 32.	2.4	26
129	Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic. Movement Disorders, 2018, 33, 684-696.	2.2	140

#	Article	IF	Citations
130	LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. Parkinsonism and Related Disorders, 2018, 52, 98-101.	1.1	25
131	Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and metaâ€analyses. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 232-241.	1.1	49
132	Biomarkers for cognitive dysfunction in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 46, S19-S23.	1.1	37
133	Molecular mechanisms of Î±-synuclein and GBA1 in Parkinsonâ€™s disease. Cell and Tissue Research, 2018, 373, 51-60.	1.5	77
134	Glucocerebrosidase expression patterns in the non-human primate brain. Brain Structure and Function, 2018, 223, 343-355.	1.2	9
135	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
136	Dementia with Lewy bodies and Parkinsonâ€™s disease-dementia: current concepts and controversies. Journal of Neural Transmission, 2018, 125, 615-650.	1.4	200
137	Glucocerebrosidase mutations and parkinsonism: how much does the mutation matter?. Journal of Xiangya Medicine, 0, 3, 1-1.	0.2	3
138	Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes. Movement Disorders, 2018, 33, 1656-1660.	2.2	14
139	Glucocerebrosidase deficiency promotes protein aggregation through dysregulation of extracellular vesicles. PLoS Genetics, 2018, 14, e1007694.	1.5	30
140	Biochemical and molecular characterization of adult patients with type I Gaucher disease and carrier frequency analysis of Leu444Pro - a common Gaucher disease mutation in India. BMC Medical Genetics, 2018, 19, 178.	2.1	12
141	Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum. Molecular Genetics and Metabolism Reports, 2018, 17, 69-72.	0.4	4
142	Reduced glucocerebrosidase activity in monocytes from patients with Parkinsonâ€™s disease. Scientific Reports, 2018, 8, 15446.	1.6	82
143	Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age. Scientific Reports, 2018, 8, 15207.	1.6	24
144	The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. , 2018, 08, .		80
145	New Frontiers in Parkinson's Disease: From Genetics to the Clinic. Journal of Neuroscience, 2018, 38, 9375-9382.	1.7	32
146	Lewy Body Dementia. Clinics in Geriatric Medicine, 2018, 34, 603-615.	1.0	52
147	Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism and Related Disorders, 2018, 55, 45-49.	1.1	90

#	Article	IF	Citations
148	Reply: Lysosomal storage disorder gene variants in multiple system atrophy. Brain, 2018, 141, e54-e54.	3.7	0
149	Lysosomes, autophagosomes and Alzheimer pathology in dementia with Lewy body disease. Neuropathology, 2018, 38, 347-360.	0.7	5
150	Glucocerebrosidase mRNA is Diminished in Brain of Lewy Body Diseases and Changes with Disease Progression in Blood. , 2018, 9, 208.		14
151	Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes. Frontiers in Neuroanatomy, 2018, 12, 52.	0.9	19
152	Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Frontiers in Neuroscience, 2018, 12, 230.	1.4	21
153	Integrated Genetic Analysis of Racial Differences of Common GBA Variants in Parkinson's Disease: A Meta-Analysis. Frontiers in Molecular Neuroscience, 2018, 11, 43.	1.4	71
154	Acid ceramidase inhibition ameliorates Î±-synuclein accumulation upon loss of GBA1 function. Human Molecular Genetics, 2018, 27, 1972-1988.	1.4	53
155	The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions. Current Neurology and Neuroscience Reports, 2018, 18, 67.	2.0	69
156	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurology, The, 2018, 17, 597-608.	4.9	101
157	The genetics of dementia with Lewy bodies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 431-440.	1.0	1
158	GBA-Associated Parkinsonâ€™s Disease and Other Synucleinopathies. Current Neurology and Neuroscience Reports, 2018, 18, 44.	2.0	106
159	The GBA p.Trp378Gly mutation is a probable Frenchâ€Canadian founder mutation causing Gaucher disease and synucleinopathies. Clinical Genetics, 2018, 94, 339-345.	1.0	9
160	Dementia associated with disorders of the basal ganglia. Journal of Neuroscience Research, 2019, 97, 1728-1741.	1.3	10
161	Age-related neurochemical and behavioural changes in D409V/WT GBA1 mouse: Relevance to lewy body dementia. Neurochemistry International, 2019, 129, 104502.	1.9	10
162	Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?. Trends in Neurosciences, 2019, 42, 631-643.	4.2	22
163	Lipids as Trans-Acting Effectors for Î±-Synuclein in the Pathogenesis of Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 693.	1.4	15
164	Soluble expression and purification of high-bioactivity recombinant human bone morphogenetic protein-2 by codon optimisation in Escherichia coli. Protein Engineering, Design and Selection, 2019, 32, 153-157.	1.0	2
166	ARSA variants in Î±-synucleinopathies. Brain, 2019, 142, e70-e70.	3.7	17

#	Article	IF	Citations
167	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. Movement Disorders, 2019, 34, 1406-1422.	2.2	62
168	Progress in the genetic analysis of Parkinsonâ€™s disease. Human Molecular Genetics, 2019, 28, R215-R218.	1.4	27
169	Dementia with Lewy bodies: an update and outlook. Molecular Neurodegeneration, 2019, 14, 5.	4.4	203
170	Insights into GBA Parkinson's disease pathology and therapy with induced pluripotent stem cell model systems. Neurobiology of Disease, 2019, 127, 1-12.	2.1	13
171	Glucocerebrosidase regulators SCARB2 and TFEB are up-regulated in Lewy body disease brain. Neuroscience Letters, 2019, 706, 164-168.	1.0	2
172	GBA and APOE Îµ4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Scientific Reports, 2019, 9, 7013.	1.6	53
173	Parkinson's and Lewy body dementia CSF biomarkers. Clinica Chimica Acta, 2019, 495, 318-325.	0.5	38
174	C-terminal Îł-synuclein truncations are linked to cysteine cathepsin activity in Parkinsonâ€™s disease. Journal of Biological Chemistry, 2019, 294, 9973-9984.	1.6	48
176	GBA, Gaucher Disease, and Parkinsonâ€™s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells, 2019, 8, 364.	1.8	187
177	Neurochemical Aspects of Lewy Body Dementia. , 2019, , 113-150.		0
178	Necrosis, apoptosis, necroptosis, three modes of action of dopaminergic neuron neurotoxins. PLoS ONE, 2019, 14, e0215277.	1.1	51
179	Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies â€“ current issues and future directions. Journal of Neurochemistry, 2019, 150, 467-474.	2.1	98
180	First Clinicogenetic Description of Parkinson's Disease Related to GBA Mutation S107L. Movement Disorders Clinical Practice, 2019, 6, 254-258.	0.8	4
181	Review: Clinical, neuropathological and genetic features of Lewy body dementias. Neuropathology and Applied Neurobiology, 2019, 45, 635-654.	1.8	26
182	Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies. Clinica Chimica Acta, 2019, 495, 13-24.	0.5	18
183	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
184	GBA1-associated parkinsonism: new insights and therapeutic opportunities. Current Opinion in Neurology, 2019, 32, 589-596.	1.8	42
185	Impaired Î²-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations. Acta Neuropathologica Communications, 2019, 7, 218.	2.4	47

#	Article	IF	Citations
186	Genome sequencing for early-onset or atypical dementia: high diagnostic yield and frequent observation of multiple contributory alleles. Journal of Physical Education and Sports Management, 2019, 5, a003491.	0.5	25
187	Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy, 2019, 15, 113-130.	4.3	155
188	Path mediation analysis reveals GBA impacts Lewy body disease status by increasing Î±-synuclein levels. Neurobiology of Disease, 2019, 121, 205-213.	2.1	43
189	Dementia with Lewy bodies â€" from scientific knowledge to clinical insights. Nature Reviews Neurology, 2019, 15, 103-112.	4.9	49
190	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Movement Disorders, 2019, 34, 9-21.	2.2	73
191	The role of monogenic genes in idiopathic Parkinsonâ€™s disease. Neurobiology of Disease, 2019, 124, 230-239.	2.1	97
192	New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics. Parkinsonism and Related Disorders, 2019, 59, 32-38.	1.1	25
193	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
194	Genetics of REM Sleep Behavior Disorder. , 2019, , 589-609.		2
195	Genetic screening in early-onset Alzheimer's disease identified three novel presenilin mutations. Neurobiology of Aging, 2020, 86, 201.e9-201.e14.	1.5	16
196	Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. Human Molecular Genetics, 2020, 29, 716-726.	1.4	48
197	Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases. Movement Disorders, 2020, 35, 5-19.	2.2	60
198	Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alphaâ€Synuclein Profiles. Movement Disorders, 2020, 35, 495-499.	2.2	32
199	A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson's disease. Neurobiology of Disease, 2020, 134, 104647.	2.1	50
200	Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological Î±-Synuclein Insult. Neuron, 2020, 105, 822-836.e7.	3.8	89
201	Systematic review of genetic association studies in people with Lewy body dementia. International Journal of Geriatric Psychiatry, 2020, 35, 436-448.	1.3	17
202	Family History is Associated with Phenotype in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2020, 73, 269-275.	1.2	2
203	Clinical Evaluation of Sibling Pairs With Gaucher Disease Discordant for Parkinsonism. Movement Disorders, 2020, 35, 359-365.	2.2	10

#	Article	IF	Citations
204	Cell type-specific lipid storage changes in Parkinsonâ€™s disease patient brains are recapitulated by experimental glycolipid disturbance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27646-27654.	3.3	59
205	Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in Parkinsonism. Trends in Molecular Medicine, 2020, 26, 913-923.	3.5	36
206	The complex relationship between genotype, pathology and phenotype in familial dementia. Neurobiology of Disease, 2020, 145, 105082.	2.1	6
207	Trends in Glucocerebrosides Research: A Systematic Review. Frontiers in Physiology, 2020, 11, 558090.	1.3	2
208	GBA variation and susceptibility to multiple system atrophy. Parkinsonism and Related Disorders, 2020, 77, 64-69.	1.1	12
209	<scp>GBA</scp> Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes. Movement Disorders, 2020, 35, 2201-2210.	2.2	55
210	Assessment of genetic risk for improved clinical-neuropathological correlations. Acta Neuropathologica Communications, 2020, 8, 160.	2.4	4
211	GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds. Frontiers in Cell and Developmental Biology, 2020, 8, 562522.	1.8	10
212	Glucocerebrosidase deficiency promotes release of Î±-synuclein fibrils from cultured neurons. Human Molecular Genetics, 2020, 29, 1716-1728.	1.4	35
213	Epigenetic regulation in the pathophysiology of Lewy body dementia. Progress in Neurobiology, 2020, 192, 101822.	2.8	10
214	Insulin resistance and Parkinsonâ€™s disease. , 2020, , 293-347.		0
215	Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 271.	1.8	40
216	Common Variants Coregulate Expression of <scp>GBA</scp> and Modifier Genes to Delay Parkinson's Disease Onset. Movement Disorders, 2020, 35, 1346-1356.	2.2	30
217	Mutated ATP10B increases Parkinsonâ€™s disease risk by compromising lysosomal glucosylceramide export. Acta Neuropathologica, 2020, 139, 1001-1024.	3.9	46
218	Glucocerebrosidase: Functions in and Beyond the Lysosome. Journal of Clinical Medicine, 2020, 9, 736.	1.0	37
219	Molecular profiling in Parkinsonian syndromes: CSF biomarkers. Clinica Chimica Acta, 2020, 506, 55-66.	0.5	2
220	GBA variants in REM sleep behavior disorder. Neurology, 2020, 95, e1008-e1016.	1.5	45
221	Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease. CNS Drugs, 2020, 34, 915-923.	2.7	14

#	Article	IF	Citations
222	Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy. International Journal of Molecular Sciences, 2020, 21, 4718.	1.8	15
223	Mutation Analysis of the Genes Associated with Parkinsonâ€™s Disease in a Finnish Cohort of Early-Onset Dementia. Journal of Alzheimer's Disease, 2020, 76, 955-965.	1.2	0
224	Longitudinal Positron Emission Tomography of Dopamine Synthesis in Subjects with GBA1 Mutations. Annals of Neurology, 2020, 87, 652-657.	2.8	12
225	Lysosome and Inflammatory Defects in GBA1â€Mutant Astrocytes Are Normalized by LRRK2 Inhibition. Movement Disorders, 2020, 35, 760-773.	2.2	79
226	Innate Immunity: A Common Denominator between Neurodegenerative and Neuropsychiatric Diseases. International Journal of Molecular Sciences, 2020, 21, 1115.	1.8	70
227	Genetic architecture of neurodegenerative dementias. Neuropharmacology, 2020, 168, 108014.	2.0	5
228	Fabry Disease With Concomitant Lewy Body Disease. Journal of Neuropathology and Experimental Neurology, 2020, 79, 378-392.	0.9	16
229	Mechanisms of alpha-synuclein toxicity: An update and outlook. Progress in Brain Research, 2020, 252, 91-129.	0.9	49
230	Glucocerebrosidase Defects as a Major Risk Factor for Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 97.	1.7	65
231	Possible Role of Amyloidogenic Evolvability in Dementia with Lewy Bodies: Insights from Transgenic Mice Expressing P123H Î²-Synuclein. International Journal of Molecular Sciences, 2020, 21, 2849.	1.8	2
232	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. Brain Stimulation, 2020, 13, 1031-1039.	0.7	39
233	Substrate reduction therapy using Genzâ€667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease. Journal of Neurochemistry, 2021, 156, 692-701.	2.1	16
234	Comprehensive Analysis of Familial Parkinsonism Genes in Rapidâ€Eyeâ€Movement Sleep Behavior Disorder. Movement Disorders, 2021, 36, 235-240.	2.2	11
235	The Role of Cholesterol in <scp>Î±â€Synuclein</scp> and Lewy Body Pathology in <scp>GBA1</scp> Parkinson's Disease. Movement Disorders, 2021, 36, 1070-1085.	2.2	59
236	Astrocytes and microglia in neurodegenerative diseases: Lessons from human in vitro models. Progress in Neurobiology, 2021, 200, 101973.	2.8	29
237	Etiology and pathogenesis of Parkinson disease. , 2021, , 121-163.e16.		2
238	Measurement of GCase Activity in Cultured Cells. Methods in Molecular Biology, 2021, 2322, 47-52.	0.4	0
240	Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers. Frontiers in Neurology, 2021, 12, 635958.	1.1	14

#	Article	IF	Citations
241	Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia. NeuroMolecular Medicine, 2021, 23, 1-24.	1.8	9
242	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
243	Current and emerging pharmacotherapy for Gaucher disease in pediatric populations. Expert Opinion on Pharmacotherapy, 2021, 22, 1489-1503.	0.9	10
244	Identification of GBA mutations among neurodegenerative disease patients from eastern India. Neuroscience Letters, 2021, 751, 135816.	1.0	10
245	The Effect of GBA Mutations and APOE Polymorphisms on Dementia with Lewy Bodies in Ashkenazi Jews. Journal of Alzheimer's Disease, 2021, 80, 1221-1229.	1.2	12
246	LRP10 interacts with SORL1 in the intracellular vesicle trafficking pathway in non-neuronal brain cells and localises to Lewy bodies in Parkinsonâ€™s disease and dementia with Lewy bodies. Acta Neuropathologica, 2021, 142, 117-137.	3.9	15
247	Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges. International Journal of Molecular Sciences, 2021, 22, 3960.	1.8	0
248	Impact of Gba2 on neuronopathic Gaucherâ€™s disease and Î±-synuclein accumulation in medaka (Oryzias) Tj ETQq1 1 0.784314 rgBT	1.3	3
249	Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease. Frontiers in Neurology, 2021, 12, 679927.	1.1	6
250	Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models. Frontiers in Neurology, 2021, 12, 681369.	1.1	10
251	Behavioral Phenotyping in a Murine Model of GBA1-Associated Parkinson Disease. International Journal of Molecular Sciences, 2021, 22, 6826.	1.8	3
252	<scp>CSF</scp> Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in <scp>PD</scp> and <scp>DLB</scp>. Movement Disorders, 2021, 36, 2595-2604.	2.2	15
253	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2021, 83, 269-279.	1.2	10
254	Lewy Bodyâ€“like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and Î±â€Synuclein Mutations. Annals of Neurology, 2021, 90, 490-505.	2.8	43
255	Glucocerebrosidase dysfunction in neurodegenerative disease. Essays in Biochemistry, 2021, 65, 873-883.	2.1	4
257	Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. Acta Neuropathologica, 2021, 142, 961-984.	3.9	31
258	Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings. Frontiers in Neurology, 2021, 12, 648588.	1.1	23
259	Gene Therapy for Parkinsonâ€™s Disease Associated with GBA1 Mutations. Journal of Parkinson's Disease, 2021, 11, S183-S188.	1.5	30

#	Article	IF	Citations
260	Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. Free Radical Biology and Medicine, 2021, 175, 42-55.	1.3	12
261	Parkinson's disease: Genetic-driven therapeutic approaches. , 2021, , 135-159.		0
262	Progress in generating iPSC-derived dopaminergic neurons as accurate models of neurodegenerative disease. , 2021, , 181-203.		0
263	Complexity of Genotype-Phenotype Correlations in Mendelian Disorders: Lessons from Gaucher Disease. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 69-90.	0.6	5
264	Genetic architecture of common non-Alzheimerâ€™s disease dementias. Neurobiology of Disease, 2020, 142, 104946.	2.1	27
265	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	2.4	27
266	The SPID-GBA study. Neurology: Genetics, 2020, 6, e523.	0.9	37
267	Tool Compounds Robustly Increase Turnover of an Artificial Substrate by Glucocerebrosidase in Human Brain Lysates. PLoS ONE, 2015, 10, e0119141.	1.1	11
268	Reducing GBA2 Activity Ameliorates Neuropathology in Niemann-Pick Type C Mice. PLoS ONE, 2015, 10, e0135889.	1.1	61
269	Pathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinsonâ€™s Disease. , 0, , 45-64.		5
271	Patient-specific pluripotent stem cell-based Parkinsonâ€™s disease models showing endogenous alpha-synuclein aggregation. BMB Reports, 2019, 52, 349-359.	1.1	11
272	Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity. Movement Disorders, 2021, 36, 2719-2730.	2.2	22
273	New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. Neuropharmacology, 2022, 202, 108822.	2.0	33
274	TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinsonâ€™s disease. Neuron, 2021, 109, 3758-3774.e11.	3.8	26
275	Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Scientific Reports, 2021, 11, 20945.	1.6	14
276	Dementia with Lewy Bodies. , 2014, , 155-177.		0
277	Genetics of Dementia with Lewy Bodies. , 2015, , 65-74.		0
279	8 Role of iPSCs in Disease Modeling: Gaucher Disease and Related Disorders. , 2017, , 161-176.		0

#	Article	IF	Citations
281	Probable role of Arthrospira platensis in neurodegenerative disorder as neuroprotective agent. IP International Journal of Comprehensive and Advanced Pharmacology, 2019, 4, 29-33.	0.1	0
285	Linking glucocerebrosidase gene (GBA) variants and Parkinson's disease. , 2020, , 67-81.		1
287	Psychosis in Gaucher's Disease. Psychiatric Annals, 2020, 50, 317-320.	0.1	0
288	Parkinson disease and related disorders. , 2020, , 19-30.		1
289	New macrophage models of Gaucher disease offer new tools for drug development. Macrophage, 2015, 2, e712.	1.0	1
290	Gaucher Disease: New Expanded Classification Emphasizing Neurological Features. Iranian Journal of Child Neurology, 2019, 13, 7-24.	0.2	6
291	Parkinson's Disease Associated with GBA Gene Mutations: Molecular Aspects and Potential Treatment Approaches. Acta Naturae, 2021, 13, 70-78.	1.7	1
292	Parkinsonâ€™s Disease Associated with GBA Gene Mutations: Molecular Aspects and Potential Treatment Approaches. Acta Naturae, 2021, 13, 70-78.	1.7	6
294	Lewy body disease or diseases with Lewy bodies?. Npj Parkinson's Disease, 2022, 8, 3.	2.5	26
295	Roles of Î±-Synuclein and Disease-Associated Factors in Drosophila Models of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 1519.	1.8	8
296	Genetics of cognitive dysfunction in Parkinson's disease. Progress in Brain Research, 2022, 269, 195-226.	0.9	6
297	Update on CSF Biomarkers in Parkinsonâ€™s Disease. Biomolecules, 2022, 12, 329.	1.8	29
298	Discovery of Brain-Penetrant Glucosylceramide Synthase Inhibitors with a Novel Pharmacophore. Journal of Medicinal Chemistry, 2022, 65, 4270-4290.	2.9	10
299	HEPESâ€buffering of bicarbonateâ€containing culture medium perturbs lysosomal glucocerebrosidase activity. Journal of Cellular Biochemistry, 2022, 123, 893-905.	1.2	2
300	Delineating the Neuropathology of Lysosomal Storage Diseases Using Patient-Derived Induced Pluripotent Stem Cells. Stem Cells and Development, 2022, 31, 221-238.	1.1	2
301	Effect of GBA gene variants on clinical characteristics of dementia with Lewy bodies: a review and meta-analyses. Neurological Sciences, 2022, 43, 3541-3550.	0.9	4
302	Predictors of RBD progression and conversion to synucleinopathies. Current Neurology and Neuroscience Reports, 2022, 22, 93-104.	2.0	13
303	Monogenetic Forms of Parkinsonâ€™s Disease â€“ Bridging the Gap Between Genetics and Biomarkers. Frontiers in Aging Neuroscience, 2022, 14, 822949.	1.7	1

#	Article	IF	Citations
304	Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments. Neurobiology of Disease, 2022, 166, 105663.	2.1	34
305	Lipid Metabolism Influence on Neurodegenerative Disease Progression: Is the Vehicle as Important as the Cargo?. Frontiers in Molecular Neuroscience, 2021, 14, 788695.	1.4	28
323	Exploring the Role of Ubiquitinâ€“Proteasome System in Parkinson's Disease. Molecular Neurobiology, 2022, 59, 4257-4273.	1.9	24
324	Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism. International Journal of Molecular Sciences, 2022, 23, 5842.	1.8	8
325	High-throughput analysis of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosing. Molecular Therapy, 2022, 30, 3209-3225.	3.7	4
326	GBA-associated PD: chances and obstacles for targeted treatment strategies. Journal of Neural Transmission, 2022, 129, 1219-1233.	1.4	22
327	Neuroprotective approaches to halt Parkinson's disease progression. Neurochemistry International, 2022, 158, 105380.	1.9	7
328	Recent advances in Lewy body dementia: A comprehensive review. Disease-a-Month, 2023, 69, 101441.	0.4	3
329	Multi-Omics Interdisciplinary Research Integration to Accelerate Dementia Biomarker Development (MIRIADE). Frontiers in Neurology, 0, 13, .	1.1	10
330	Ceramide and Sphingosine-1-Phosphate in Neurodegenerative Disorders and Their Potential Involvement in Therapy. International Journal of Molecular Sciences, 2022, 23, 7806.	1.8	8
331	Clinical impact of whole-genome sequencing in patients with early-onset dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1181-1189.	0.9	7
332	Î²-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration. Cells, 2022, 11, 2343.	1.8	8
333	Comprehensive short and long read sequencing analysis for the Gaucher and Parkinsonâ€™s disease-associated GBA gene. Communications Biology, 2022, 5, .	2.0	14
334	Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review. Neuroscience and Biobehavioral Reviews, 2022, 141, 104856.	2.9	2
336	Machine learning-based prediction of cognitive outcomes in de novo Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, .	2.5	6
338	Exploring the Sensitivity of Prodromal Dementia with Lewy Bodies Research Criteria. Brain Sciences, 2022, 12, 1594.	1.1	1
339	Plasma sphingolipid abnormalities in neurodegenerative diseases. PLoS ONE, 2022, 17, e0279315.	1.1	6
341	Sex differences in dementia with Lewy bodies: Focused review of available evidence and future directions. Parkinsonism and Related Disorders, 2023, 107, 105285.	1.1	12

#	Article	IF	Citations
342	The Consequences of GBA Deficiency in the Autophagyâ€“Lysosome System in Parkinsonâ€™s Disease Associated with GBA. Cells, 2023, 12, 191.	1.8	9
343	GBA1 Gene Mutations in Î±-Synucleinopathiesâ€”Molecular Mechanisms Underlying Pathology and Their Clinical Significance. International Journal of Molecular Sciences, 2023, 24, 2044.	1.8	10
344	Genetic Testing in Clinical Movement Disorders: A Case-Based Review. Seminars in Neurology, 2023, 43, 147-155.	0.5	0
345	Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease. Movement Disorders, 2023, 38, 899-903.	2.2	3
346	The genetic basis of multiple system atrophy. Journal of Translational Medicine, 2023, 21, .	1.8	5
347	Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 187-218.	1.0	1
348	Genetic mechanism vs genetic subtypes: The example of GBA. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 155-170.	1.0	3
349	Mechanisms of Glucocerebrosidase Dysfunction in Parkinsonâ€™s Disease. Journal of Molecular Biology, 2023, 435, 168023.	2.0	7
350	Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. , 2023, 246, 108419.		3